as per attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.8 pts more than Nifty Microcap 250 and 9.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjivani Paranteral reported strong FY25 results with revenue from operations rising to ₹7,009.86 lakhs from ₹5,441.05 lakhs, a growth of about 29% year-on-year. Net profit (standalone) grew to ₹810.18 lakhs from ₹616.51 lakhs, up roughly 31%, while basic EPS rose to ₹6.89 from ₹5.28. Q4 was particularly strong, with revenue up about 41% and net profit up about 74% versus Q4 FY24. The company also shared operational updates: commercial production has begun at its 45%-owned nutraceutical facility in Prague (EU), the new IV fluid plant in Pune is ready with validation batches underway and a 90-day forward order book already in hand, and it has cleared regulatory audits for five new export markets. The auditor (R.B. Gohil & Co.) gave an unmodified opinion on both standalone and consolidated results.
Positive: healthy top-line and bottom-line growth, expanded global footprint and a new IV plant coming online support the growth story. Watch-item: trade receivables jumped sharply to ₹1,667.92 lakhs (from ₹469.74 lakhs) and standalone operating cash flow remained marginally negative, so collection efficiency is worth tracking.